Cystic Fibrosis: Meveol effective against Burkholderia Dolosa
The new generation of antimicrobial confirmed its potential with the evidence of effectiveness on this resistant bacterium kindly provided by Harvard Children's Hospital for which no therapeutic solution is available to date
Apr 07, 2011 – Alaxia, a Lyons biotech that is developing the candidate drug Meveol hired an independent certified laboratory to confirm in vitro efficacy recorded by its microbiologists. The effect of Meveol has been studied on several strains of Burkholderia dolosa. Meveol bactericidal efficacy - over 99.9% - is observed in a few hours.
These results were obtained as part of a research partnersh...
Source: Alaxia - April 7, 2011 Category: Respiratory Medicine Source Type: news
Efficacy also shown on Mycobacteria for Meveol
Further to some clinician request, Alaxia ordered an independant lab, CER in Belgium, to test Meveol efficacy vs atypical mycobacteria. Meveol shows high efficacy vs this strong pathogenic strain.
We remind you Meveol is effective not only on Pseudomonas but on wide spectrum of bacteria including positive and negative gram Burkholderia, Pseudomonas even in biofilm form. (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - June 28, 2010 Category: Respiratory Medicine Source Type: news
Hypothiocyanite/lactoferrin
Alaxia announce today, it's product, Meveol (hypothiocyanite/lactoferrin) has been designated Orphan drug by FDA, for Cystic Fibrosis. We remind you Meveol has been especially designed in order to compensate innate lung pulmonary defence system, deficient in CF;
Many papers available on Pubmed (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - November 22, 2009 Category: Respiratory Medicine Source Type: news
A new tool for Cystic Fibrosis
Alaxia announces today its product, meveol, has been tested successfully by an independant lab on strong strains including mucoid pseudomonas, burkholderia, MRSA both In Vitro and In Vivo Meveol targets to compensate natural host defence defective in cystic fibrosis (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
Alaxia
is a young biotech company dedicated to orphan diseases and especially to cystic fibrosis. Alaxia, located in Lyon area, develops Meveol, a new antimicrobial product (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
A new tool for Cystic Fibrosis
Alaxia announces today its product, meveol, has been tested successfully by an independant lab on strong strains including mucoid pseudomonas, burkholderia, MRSA both In Vitro and In Vivo Meveol targets to compensate natural host defence defective in cystic fibrosis (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
Alaxia
is a young biotech company dedicated to orphan diseases and especially to cystic fibrosis. Alaxia, located in Lyon area, develops Meveol, a new antimicrobial product (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
A new tool for Cystic Fibrosis
Alaxia announces today its product, meveol, has been tested successfully by an independant lab on strong strains including mucoid pseudomonas, burkholderia, MRSA both In Vitro and In Vivo Meveol targets to compensate natural host defence defective in cystic fibrosis (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
Alaxia
is a young biotech company dedicated to orphan diseases and especially to cystic fibrosis. Alaxia, located in Lyon area, develops Meveol, a new antimicrobial product (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia) (Source: Alaxia)
Source: Alaxia - March 27, 2009 Category: Respiratory Medicine Source Type: news
